FDA approves Lisraya as first oral drug for dermatomyositis

medpagetoday.com·Aug 27, 2026 · 2 g fa

First Oral Option for Dermatomyositis Gets FDA Green Light

biopharmadive.com·Aug 28, 2026 · 2 g fa

FDA green lights Priovant drug for rare skin disease

endpoints.news·Aug 27, 2026 · 2 g fa

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

morningstar.com·Aug 28, 2026 · 1 g fa

Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)

statnews.com·Aug 27, 2026 · 2 g fa

FDA approves Roivant therapy for rare autoimmune disease

morningstar.com·Aug 29, 2026 · 23 h fa

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

endpoints.news·Aug 29, 2026 · 1 g fa

FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder

fiercepharma.com·Aug 28, 2026 · 1 g fa

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

morningstar.com·Aug 29, 2026 · 1 g fa

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera